Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Therapy-Induced Erythrocytosis in Thyroid Cancers: An Underrecognized Safety Signal from a Retrospective Study.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Evidence of increased awareness in cardiac amyloidosis, but still room for improvement.

European journal of internal medicine·2026
Same author

Efgartigimod as a treatment for adults with primary immune thrombocytopenia: a plain language summary of the ADVANCE IV study.

Therapeutic advances in hematology·2026
Same author

Management of mild hand-foot syndrome associated with medical cancer therapies with an alcohol-free moisturizing and reparative gel containing omental lipids, urea, bromelain, and carnosine: a pilot prospective 12-week study.

Dermatology reports·2026
Same author

Trends in cardiac amyloidosis hospital admissions and associated mortality risk over 20 years: a population-based study using healthcare administrative databases.

European journal of internal medicine·2026
Same author

A 50+ Sunscreen Containing Polypodium Leucotomos Extract, Ellagic Acid, and Niacinamide in Facial Melasma and Photoaging-Related Hyperpigmentation: A Pilot Observational Study Using Line-Field Confocal Optical Coherence Tomography.

Journal of cosmetic dermatology·2026

Related Experiment Video

Updated: Jun 25, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

D-dimer before chemotherapy might predict venous thromboembolism.

Guido Arpaia1, Monica Carpenedo, Magda Verga

  • 1Department of Medicine, Azienda Ospedaliera Ospedale Civile di Vimercate, Vimercate, Italy. guido.arpaia@tin.it

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|March 12, 2009
PubMed
Summary

Elevated D-dimer levels in cancer patients undergoing chemotherapy indicate a higher risk of venous thrombotic events (VTE). Baseline D-dimer can identify patients unlikely to develop VTE, potentially avoiding unnecessary prophylaxis.

Related Experiment Videos

Last Updated: Jun 25, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Area of Science:

  • Oncology
  • Hematology
  • Diagnostic Medicine

Background:

  • Cancer patients receiving chemotherapy face a significantly increased risk of venous thromboembolism (VTE), approximately 6.5-fold higher than the general population.
  • Current guidelines do not routinely recommend VTE prophylaxis for these patients due to concerns about bleeding risk.
  • Identifying high-risk individuals is crucial for targeted preventative strategies.

Purpose of the Study:

  • To evaluate the utility of baseline D-dimer levels in identifying cancer patients at high risk for VTE during chemotherapy.
  • To determine the optimal benefit/risk ratio for VTE prophylaxis based on D-dimer levels.

Main Methods:

  • A prospective study involving 124 cancer patients scheduled for their first chemotherapy cycle.
  • Baseline D-dimer levels were measured, and VTE events (symptomatic and asymptomatic deep vein thrombosis, pulmonary embolism) were monitored for 6 months.
  • Compression ultrasonography was used to detect asymptomatic deep vein thrombosis at baseline and at 90 and 180 days.

Main Results:

  • 11 VTE events (8.9%) occurred during the follow-up period.
  • Patients with VTE had significantly higher mean baseline D-dimer levels (2195 ng/ml) compared to those without VTE (695 ng/ml).
  • Patients in the highest tertile of D-dimer levels (>650 ng/dl) had a substantially higher incidence of VTE (22%) compared to those in the lower tertiles (2.4%), with a relative risk of 11.0 for VTE development.

Conclusions:

  • Baseline D-dimer concentration is a significant independent predictor of VTE development in cancer patients undergoing chemotherapy.
  • Low baseline D-dimer levels (<650 ng/ml) may identify patients at low risk for VTE, suggesting they could be safely managed without prophylactic anticoagulation.